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Abstract
Background: Brucella, a Gram-negative bacterium, is classified as a potential bioterrorism agent mainly due to the low
dose needed to cause infection and the ability to transmit the bacteria via aerosols. Goats/sheep, cattle, pigs, dogs, sheep
and rodents are infected by B. melitensis, B. abortus, B. suis, B. canis, B. ovis and B. neotomae, respectively, the six classical
Brucella species. Most human cases are caused by B. melitensis and B. abortus. Our aim was to specifically detect Brucellae
with ‘smooth’ lipopolysaccharide (LPS) using a highly sensitive monoclonal antibody (mAb) based immunological assay.
Methods: To complement molecular detection systems for potential bioterror agents, as required by international
biodefense regulations, sets of mAbs were generated by B cell hybridoma technology and used to develop
immunological assays. The combination of mAbs most suitable for an antigen capture assay format was identified and an
immunoassay using the Luminex xMAP technology was developed.
Results: MAbs specific for the LPS O-antigen of Brucella spp. were generated by immunising mice with inactivated
B. melitensis or B. abortus cells. Most mAbs recognised both B. melitensis and B. abortus and antigen binding was not
impeded by inactivation of the bacterial cells by γ irradiation, formalin or heat treatment, a step required to analyse the
samples immunologically under biosafety level two conditions. The Luminex assay recognised all tested Brucella
species with ‘smooth’ LPS with detection limits of 2 × 102 to 8 × 104 cells per mL, depending on the species tested.
Milk samples spiked with Brucella spp. cells were identified successfully using the Luminex assay. In addition, the
bead-based immunoassay was integrated into a multiplex format, allowing for simultaneous, rapid and specific
detection of Brucella spp., Bacillus anthracis, Francisella tularensis and Yersinia pestis within a single sample.
Conclusion: Overall, the robust Luminex assay should allow detection of Brucella spp. in both natural outbreak
and bio-threat situations.
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Background
Brucellosis, a zoonotic bacterial disease caused by
Gram-negative Brucellae and classified as a potential
bioterrorism disease [1], leads to abortions in animals
and flu-like symptoms with periodic bouts of fever in
humans. B. melitensis, B. abortus, B. suis, B. canis, B.
ovis and B. neotomae are the six classical species that
infect mainly goats/sheep, cattle, pigs, dogs, sheep and
rodents, respectively, while B. melitensis and B. abortus
cause most of the human infections [2–4]. Like other
Gram-negative bacteria, Brucellae express lipopolysac-
charide (LPS), a major component of the outer mem-
brane. The three structural components of LPS are the
lipid A, the core oligosaccharide and the O-
polysaccharide (O-antigen). In ‘smooth’ Brucella species,
the O-polysaccharide is a linear polymer of 4,6-dideoxy-4-
formamido-α-D-mannopyranosyl residues, whereas ‘rough’
* Correspondence: gerd.pluschke@unibas.ch
1Department of Medical Parasitology and Infection Biology, Swiss Tropical
and Public Health Institute, Basel, Switzerland
2University of Basel, Basel, Switzerland
Full list of author information is available at the end of the article
© 2015 Silbereisen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Silbereisen et al. BMC Microbiology  (2015) 15:198 
DOI 10.1186/s12866-015-0534-1
strains have a truncated version without the O-antigen
[5, 6]. Brucella LPS is able to induce protective anti-
bodies [7–9], which are potentially important for sero-
logical diagnosis [10–16]. Because of the threat posed
by natural outbreaks or by a deliberate release of the
bacteria as a bioterror agent [17], there is a need for
rapid and reliable identification systems, preferably
based on multiplex formats covering a range of relevant
species. This is especially important for fastidious agents
such as Brucella or Francisella species where tracing by
cultivation is hampered by long cultivation time.
The aim of this study was to develop a rapid and sen-
sitive immunological assay to detect all Brucellae with
‘smooth’ LPS, particularly B. melitensis and B. abortus.
To this end, monoclonal antibodies (mAbs) specific for
Brucella LPS were generated and used to design a highly
specific and sensitive antigen capture assay. An optimal
combination of mAbs was identified and a Brucella LPS
specific Luminex xMAP assay [18, 19] was developed,
capable of detecting four of the major Brucella species
(B. melitensis, B. abortus, B. suis, B. neotomae) with high
sensitivity. Additionally, the Luminex assay works in a
multiplex format, simultaneously detecting four category
A and B bacterial bioterrorism agents and is suitable for
detecting Brucella in complex samples.
Methods
Ethics statement
This study was carried out in strict accordance with the
Rules and Regulations for the Protection of Animal
Rights (Tierschutzverordnung) of the Swiss Federal Food
Safety and Veterinary Office. The protocol was granted
ethical approval by the Veterinary Office of the county
of Basel-Stadt, Switzerland (Permit Number: 2375).
Production and inactivation of bacteria
Bacterial strains used in this study are listed in Table 1.
Brucella spp. were cultured on Columbia blood agar
plates supplemented with 5 % goat blood [20]. Bacteria
were inactivated by 3 % formalin (55 °C for 15 min), heat
(60 °C for >20 h) or gamma (γ) irradiation at 30–40 kGy
(Leoni Studer Hard AG, Däniken, Switzerland). Sterility
was checked by incubating bacteria for three days on
agar plates and no growth was observed.
Production of anti-LPS mAbs
To produce Brucella LPS-specific mAbs, mice carrying
human immunoglobulin Cγ1 heavy and Cκ light chain
gene segments [21] were immunised four times sub-
cutaneously with a dose of 108 CFU of differentially
inactivated Brucella species, either adjuvant-free or as
adjuvanted formulation, in combination with the
Sigma Adjuvant System® (SAS, Sigma Aldrich). Mice
received either gamma (γ) irradiated B. melitensis in
sterile Phosphate buffered saline (PBS, Sigma Aldrich),
γ irradiated B. melitensis with SAS, formalin inacti-
vated B. melitensis in PBS or formalin inactivated B.
abortus in PBS.
Three days before cell fusion, two selected mice re-
ceived an intravenous booster injection with 108 Bru-
cella cells in PBS. Myeloma cells (PAI) were mixed 1:3
Table 1 Bacterial strains
Bacterial species Strain Inactivation
method
Source
Brucella spp. (biotype)
B. abortus (1) NCTC 10093 544 γ, formalin, heat SL
19S formalin SL
A146-10 formalin RKI
B. abortus (3) A104-10 Uckermark γ RKI
B. canis NCTC 10854 RM-666 formalin SL
B. ovis CNCTC 6741 heat RKI
B. melitensis (1) NCTC 10094 16 M γ, formalin, heat SL
ICM 3.33 formalin SL
ICM 583/2003 formalin SL
ICM 91/2004 formalin SL
102A01C2F formalin SL
A146-13 formalin RKI
A104-11 Tgb. Nr. 117518 γ RKI
B. melitensis (2) A104-12 799/97, B3898 γ RKI
B. melitensis (3) A104-13 210739, Mainz γ RKI
B. suis (1) NCTC 10316 1330 formalin SL
B. suis (2) A 104–14 Rostock heat RKI
B. neotomae A148-7 5 K33 γ RKI
Other bacteria
F. tularensis
tularensis
ATCC 6223 formalin SL
F. tularensis
holarctica
LVS, NCTC 10857 formalin SL
B. anthracis
(spores)
Böhm 73202.2000 (PX02+) formalin SL
Böhm A1 (PX01+) formalin SL
S. typhimurium ATCC 14028 formalin SL
Y. enterocolitica 310 (IT2, ST9) O9 formalin SL
Y. pestis CO92 γ, formalin SL
O. anthropi ATCC 49188 formalin SL
E. coli O:157, 15326 formalin SL
B. mallei NCTC 03709 106 formalin SL
B. pseudomallei H05410-0490 formalin SL
V. cholera O1, ATCC 14734 formalin SL
Bacteria were inactivated by 3 % formalin, heat (60 °C for >20 h) or gamma (γ)
irradiation (30–40 kGy). SL = Spiez Laboratory (Federal Office for Civil
Protection, Spiez, Switzerland). RKI = Robert Koch Institute (Berlin, Germany)
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(fusion 1) and 1:1 (fusion 2) with spleen cells from the
corresponding mouse in Iscove’s Modified Dulbecco’s
Medium (IMDM, Sigma Aldrich). Cells were fused with
1 mL of pre-warmed (37 °C) Polyethylene glycol (PEG
800, Roche), dissolved in 150 mL HAT selective medium
(IMDM 1 % 200 mM L-Glutamine (100X), 1 % Pen/Strep
(100X, [+] 10,000 Units/mL Penicillin [+] 10,000 μg/mL
Streptomycin, Gibco), 20 % FBS, HAT media supplement
50X Hybri-Max™, Sigma Aldrich) and cultured in 96-well
tissue culture plates. Cells secreting Brucella-specific IgG
were identified by ELISA coated with γ irradiated B. meli-
tensis cells (16 M). From the two independent fusions,
eleven hybridoma cell lines producing LPS specific mAbs
were identified and cloned by limiting dilution. MAbs
were purified from spent culture supernatant of the hy-
bridoma clones by protein A affinity chromatography
(HiTrap rProtein A FF, Amersham Biosciences). Puri-
fied mAbs were dialysed against PBS, aliquoted, and
stored at −80 °C.
Enzyme-linked immunosorbent assay (ELISA)
In indirect ELISA (iELISA), Maxisorp™ microtitre plates
(Nunc, Thermo Scientific) were coated for 36 h at 4 °C
with 50 μL of a 10 μg/mL solution of extracted LPS or
with 50 μL of a bacterial suspension containing 107 inac-
tivated Brucella cells per mL. Wells were then blocked
with 5 % milk powder in PBS for 2 h, followed by three
washings with PBS containing 0.25 % Tween-20. Plates
were incubated with appropriate dilutions of mouse sera
or anti-LPS mAbs in PBS for 1–2 h at room temperature.
After washing, plates were incubated with horseradish
peroxidase-conjugated goat anti-mouse IgG (γ-chain spe-
cific) antibodies (Southern Biotech) for 1 h. TMB (TMB
Microwell Peroxidase Substrate System (2-C), KPL) or
ABTS substrate (ABTS® Peroxidase Substrate System,
KPL) was added and incubated at room temperature until
appropriate colour intensity was reached (five to 30 min).
The optical density (OD) of the reaction product was re-
corded after 5 to 30 min at 570 nm or 405 nm using a mi-
croplate reader.
In antigen capture ELISA (cELISA), microtitre plates
were coated with 50 μL of a 10 μg/mL solution of un-
labelled mAbs in PBS. After being blocked and washed,
wells were incubated with dilutions of inactivated Bru-
cella cells in PBS. Biotinylated detection mAbs (10 μg/
mL) were added and incubated for 1 h. After repeated
washing, streptavidin-peroxidase polymer conjugate
(1 μg/mL, Sigma Aldrich) was added and developed
with the ABTS substrate.
Isotypes of anti-LPS mAbs were determined by de-
tecting mAbs bound to anti-mouse lambda light chain
antibody-coated plates with alkaline phosphatase-
conjugated antibodies specific for mouse IgG1, IgG2a,
IgG2b or IgG3 (Southern Biotech).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and immunoblotting
Aliquots of extracted LPS from B. melitensis and B.
abortus were mixed with sample buffer (Laemmli buffer,
Invitrogen) and heated for 15 min at 96 °C before load-
ing on 4–12 % Bis-Tris gels. SeeBlue® pre-stained protein
standard (Invitrogen) was used as a molecular weight
marker. Following gel electrophoresis, LPS was trans-
ferred electrophoretically to nitrocellulose membranes.
Blots were blocked for 2 h with 5 % milk powder in PBS,
cut into strips and then incubated with purified mAbs
(10 μg/mL) for 1 h. The strips were washed four times
for 15 min with PBS containing 0.05 % Tween-20 and
incubated with alkaline phosphatase-conjugated goat
anti-mouse IgG heavy-chain antibodies (Sigma Aldrich)
for 1 h. Strips were treated with 5-bromo-4-chloro-3-
indolylphosphate and nitroblue tetrazolium to visualise
bands.
Immunofluorescence assay (IFA)
30 μL droplets of a fixing solution containing 4 % para-
formaldehyde and 10 % PBS were placed in each well of
a pre-coated Poly-L-Lysin microscope glass slide (Diag-
nostic Microscope Slides ES-242B-AD-CE24, Thermo
Scientific). Ten μL of a bacterial suspension containing
108 γ irradiated B. melitensis (16 M) or B. abortus (544)
cells were added to each well and incubated for 30 min
at room temperature. Wells were washed five times with
PBS and then incubated for 15 min with 50 μL of block-
ing buffer containing 1 % fatty acid-free bovine serum
albumin (BSA) in PBS. Afterwards, 30 μL of 10 μg/mL
mAbs diluted in blocking buffer were added and incu-
bated for 1 h. Wells were washed five times with block-
ing buffer before 30 μL of detection antibody (Alexa
Fluor 568 (2 mg/mL, Invitrogen) conjugated donkey
anti-mouse IgG (H + L), 1:400 in blocking buffer) was
added for an additional hour. Finally, wells were washed
five times, mounted with ProLong® Gold antifade reagent
with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen)
and covered with a coverslip. Antibody binding and DNA
staining were assessed by fluorescence microscopy.
Luminex assay
Anti-LPS mAbs were coupled to magnetic beads (Bio-
Plex Pro Magnetic COOH Beads, Biorad) according to
the manufacturer's instructions and adjusted to a work-
ing concentration of 40 beads/μL in blocking buffer (1 %
BSA in PBS). In the coupling reaction, 6 μg of antibody
was applied to 5 × 105 beads. Fifty μL of working bead
mixture was used per microtitre well. Fifty μL bacterial
samples were then added to each bead-containing well
and incubated for 2 h on a microplate shaker at 37 °C in
the dark. After incubation, the plates were washed with
PBS containing 0.05 % Tween-20 and the beads were
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resuspended in 50 μL of biotinylated detection antibody
at a concentration of 10 μg/mL in blocking buffer and
incubated for 1 h. After repeated washing, 50 μL of a
streptavidin-R phycoerythrin (ProZyme Inc.) solution
was added and incubated for 30 min. The plate was then
washed and the beads resuspended in 125 μL of block-
ing buffer before loading onto the BioPlex 200 instru-
ment (Bio-Rad Laboratories). Reporter fluorescence was
measured and expressed as mean fluorescence intensity
of at least 100 beads per region. Multiplexed assays were
performed in a single well format with mAb pairs 3D12/
10G1 (Brucellae), MTA1/MTD6 [19], YPF19/YPF19 [22]
and T14/FB11 [23].
Statistical analysis
All data were obtained from experiments performed in
duplicate (at a minimum). Antigen-free controls con-
sisted of PBS (instead of sample suspended in PBS) and
were further diluted with the diluent used for the par-
ticular assay. These controls were included in each ex-
periment to determine the cut-off. Mean value, standard
deviation and LOD (limit of detection) were calculated
in Excel. Figure assembly, data transformation and non-
linear regression (sigmoidal curve, dose–response vari-
able slope) were done with GraphPad Prism.
Results
Generation and characterisation of Brucella LPS-specific
mAbs
Two mice exhibiting high ELISA IgG titres against B.
melitensis (16 M) or B. abortus (NCTC 10093 544) cells
after immunisation with inactivated bacterial cells were
chosen for the generation of Brucella LPS-specific
mAbs. Eleven hybridoma cell clones were obtained by
screening with a B. melitensis (16 M, γ irradiated, 5 ×
107 CFU/mL) whole cell ELISA. Two mAbs (3A10 and
4 F11) were generated from a mouse immunised with γ
irradiated B. melitensis, and nine (1A3, 10G1, 3D12,
2G12, 2G2, 1B6, 2E3, 5B10, 1E2) from a mouse immu-
nised with formalin inactivated B. abortus cells. Deter-
mination of the mouse IgG subclass of the produced
LPS-specific mAbs showed a predominance of the
IgG2b(λ) isotype; only mAbs 4 F11 and 1E2 were of the
IgG3(λ) isotype. While all 11 mAbs recognised extracted
LPS from B. abortus (type A O-antigen), mAbs 1E2 and
4 F11 showed a markedly weaker reactivity with B. meli-
tensis LPS (type M O-antigen) than did the others in
ELISA (Fig. 1a) and Western blotting (Fig. 1c). The
Western blot profiles (Fig. 1c) were typical for ‘smooth’
LPS of Brucella sp. [24]. In immunofluorescence analysis
with inactivated B. melitensis and B. abortus cells, all
anti-LPS mAbs yielded a homogenous circular surface
staining. Figure 1b shows a representative staining for
mAbs 3D12 and 10G1 with B. melitensis cells. The
differences in the fine-specificities of the mAbs observed
in ELISA correlated with differences in immunofluores-
cence analysis, where surface staining by mAbs 1E2 and
4 F11 with B. melitensis cells was weak (data not shown).
For the analysis of the samples under biosafety level two
conditions, inactivation is required. Different methods, γ
irradiation, formalin inactivation and heat treatment, are
available for that. Irrespective of the inactivation method,
the anti-LPS mAbs reacted with B. melitensis and B.
abortus cells in ELISA (Fig. 1d).
To develop a highly sensitive antigen capture assay, a
suitable combination of a capturing and a biotinylated-
detecting mAb was selected from the pool of 11 mAbs.
In a sandwich ELISA format, the majority of mAb com-
binations tested were suitable for detecting B. melitensis
cells (Fig. 2). Despite its weak reactivity with B. meliten-
sis LPS, mAb 1E2 could effectively be used as a capture
antibody but it failed to interact with B. melitensis cells
when used as a detection antibody. A differentiation be-
tween B. melitensis and B. abortus cells was thus only
observed with mAb 1E2 as a detection antibody (data
not shown). MAb 3D12 performed best as an antigen
capture antibody while mAb 10G1 was selected as the
detection antibody as it gave the highest read out in
combination with mAb 3D12 as the capture antibody.
Hence, further development focussed on the mAb pair
3D12/10G1.
Developing a Luminex assay for rapid and sensitive
detection of Brucella spp.
The mAb pair 3D12/10G1 was used to develop an anti-
gen capture assay based on Luminex xMAP technology.
While similar to ELISA in overall assay format, the
Luminex technology combines advanced fluidics, optics,
and digital signal processing with up to 500 color-coded
microspheres to provide an accurate measurement of
multiple analytes from a single sample [25]. Each bead
set can be conjugated to a specific biomolecule (such as
an antibody) to capture analytes of interest using a very
small sample volume. Here, the mAb 3D12 was coupled
to magnetic beads and used as the capture antibody, and
the biotinylated mAb 10G1 was used as the detection
antibody. The sensitivity of this Luminex assay was de-
termined by analysing serial dilutions of inactivated B.
melitensis, B. abortus and B. suis cells. The limit of de-
tection (LOD) was calculated as the mean fluorescence
intensity of the blank plus three times the standard devi-
ation (SD) and set as the threshold (dashed line in
Fig. 3a). The detection limits in a sample volume of
50 μL were 2 × 102 cells per mL for B. melitensis, 5 × 103
cells per mL for B. abortus and 8 × 104 cells per mL for
B. suis. Depending on the species tested, the sensitivity
of the Luminex assay was 4 to 50 times higher than that
of a corresponding antigen capture ELISA (Fig. 3b),
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where at least 104, 2 × 104 and 3 × 106 cells per mL, re-
spectively, were required for accurate detection.
The specificity of the bead-based assay was tested with
several biotypes of B. melitensis (1–3), B. abortus (1,3),
B. suis (1,2), B. canis, B. ovis and B. neotomae, as well as
with other potential bioterror agents (F. tularensis, B.
anthracis, S. typhimurium, Y. pestis, B. mallei, B. pseudo-
mallei [1]) and bacteria (Y. enterocolitica O9, E. coli
O157 and V. cholera O1 [26–29]) with structurally simi-
lar O-antigens of α1,2-linked 4-amino-4,6-dideoxy-α-D-
mannopyranosyl subunits and O. anthropi, the closest
relative of Brucellae [30]. The Luminex assay detected
all ‘smooth’ Brucella species (B. melitensis, B. abortus, B.
suis and B. neotomae) independently of their biotype
(Table 2). Overall, Brucella species expressing the M O-
antigen were detected with higher sensitivity compared
to A or AM O-antigen expressing Brucella. Cross-
reactivity with Y. enterocolitica O9 was found, as pre-
dicted by the structural identity of the type A O-antigen
[27, 28]. Neither B. canis nor B. ovis cells expressing a
‘rough’ LPS nor any of the other bacterial species tested
gave positive signals.
The newly developed singleplex assay for Brucella spp.
was integrated into a previously established multiplex
assay to allow for simultaneous detection of the four po-
tential bioterror agents, B. melitensis, B. anthracis, F.
tularensis and Y. pestis, in a single run of the assay.
Mixed samples containing combinations of the four
Fig. 1 Antigen-binding properties of the generated Brucella LPS-specific mAbs. a Reactivity of the produced mAbs with extracted B. melitensis or
B. abortus LPS in ELISA. b Western blot staining-patterns obtained with mAbs 10G1, 3D12 and 1E2 after SDS-PAGE of extracted B. melitensis and B.
abortus LPS. c Indirect immunofluorescent staining of inactivated B. melitensis (16 M) cells by mAbs 3D12 and 10G1. The upper panel shows DNA
staining with DAPI, the middle panel Alexa 568-specific immunofluorescence staining and the lower panel merged pictures of both stainings.
d Reactivity of mAb 3D12 with gamma, formalin and heat inactivated B. melitensis (16 M) and B. abortus (544) cells in ELISA
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bacterial species were prepared in PBS and tested in the
multiplexed immunoassay format (Fig. 4a). All four bio-
threat agents tested were accurately detected and no
cross-reactivities between individual singleplex assays
were observed. The specificity of the Luminex assay for B.
anthracis, F. tularensis and Y. pestis had been tested prior
to the multiplex testing (Additional files 1 and 2).
In addition, the multiplex assay specifically identified
all four bacterial species from a spiked milk sample, in-
dicating that the newly developed Luminex assay is also
suitable for detecting Brucella spp. in complex biological
samples (Fig. 4b).
Discussion
Brucellosis is one of the most common bacterial zoo-
nosis worldwide and an important cause of economic
losses and human suffering [2, 4]. Moreover, B. abortus,
B. melitensis and B. suis could be developed as bioterror-
ism agents due to their ability to undergo aerosolization
[31]. Isolation by cultivation is the standard method for
identifying Brucella bacteria in biological samples, but
may take up to 4 weeks to complete. Methods based on
the polymerase chain reaction that identifies nucleic acid
fragments from bacteria are becoming more practical
for detecting Brucella spp. [32, 33]. However, according
to international biodefense regulations, immunological
detection methods for potential bioterror agents are re-
quired in addition to molecular detection and identifi-
cation assays.
In this study, we showed that Brucella O-antigen-
specifc mAbs represent potent immuno-capturing
components for a highly sensitive detection system for
Brucella cells in complex samples. Immunisation of la-
boratory mice with inactivated Brucella bacteria combined
with a B. melitensis whole cell ELISA for selecting B-cell
hybridoma lines that produce Brucella-specific antibodies
yielded exclusively LPS-specific mAbs, although anti-
protein IgG antibodies could also be detected in the serum
of the immunised mice (data not shown). This observation
might be explained by the fact that in ‘smooth’ Brucella
species, outer membrane proteins and other membrane
components are masked by O-polysaccharide chains of
Fig. 2 Comparative testing of mAb pairs in an antigen capture
ELISA. To evaluate optimal antibody combinations, each of the 11
mAbs was used as a capture or detection (biotin-conjugate) antibody
at a concentration of 10 μg/mL. Optical densities were measured for
each antibody combination using gamma-irradiated B. melitensis
(16 M) cells at a concentration of 107 cells/mL
Fig. 3 Comparison of the sensitivity of the bead-based Luminex immunoassay (a) and the corresponding antigen capture ELISA (b). Assay
sensitivities were determined by analysing serial dilutions of inactivated B. melitensis (16 M, γ), B. abortus (544, γ) and B. suis (1330, formalin)
cells. Dashed lines indicate the assay dependent limit of detection (LOD) defined as mean blank (i.e. the no-antigen control) plus three times
the standard deviation (SD)
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LPS [34, 35]. All of the mAbs generated recognised LPS
from B. abortus (type A O-antigen) and from B. melitensis
(type M O-antigen). However, mAbs 1E2 and 4 F11 dif-
fered from the other mAbs in fine-specificity in that they
showed a markedly reduced reactivity with B. melitensis
LPS. None of the sample inactivation methods tested
(gamma irradiation, formalin and heat treatment) affected
the interaction between the mAbs produced and the bac-
terial cells, corroborating the suitability of Brucella LPS as
a stable target antigen for detection. Dependent on infra-
structural constraints (i.e. availability of gamma
irradiation) and application, laboratories may have differ-
ent preferences concerning the inactivation method.
As expected from the comparative binding studies, the
majority of the mAb combinations tested were suitable
for detecting Brucella cells in a sandwich capture ELISA
format. A differentiation between B. melitensis and other
Brucella species expressing ‘smooth’ LPS was achieved
with mAb 1E2 in a suitable test format. The Luminex
immunoassay with the selected mAb pair, 3D12 and
10G1, captured and detected cells of all ‘smooth’ Bru-
cella species and biotypes tested but also showed cross-
Table 2 Specificity of the developed bead-based Luminex immunoassay
Bacterial species Strain O-Antigen Luminex assay (mean fluorescence intensity)
Brucella spp. (biotype)
B. abortus (1) NCTC 10093 544 A1,3 13107
19S A1,3 11300
A146-10 A1,3 5607
B. abortus (3) A104-10 Uckermark A1,3 3172
B. canis NCTC 10854 RM-666 R2,3 33
B. ovis CNCTC 6741 R2,3 23
B. melitensis (1) NCTC 10094 16 M M1,3 25860
ICM 3.33 M1,3 13129
ICM 583/2003 M1,3 16972
ICM 91/2004 M1,3 15030
102A01C2F M1,3 22285
A146-13 M1,3 11407
A104-11 Tgb. Nr. 117518 M1,3 5977
B. melitensis (2) A104-12 799/97, B3898 A1,3 2958
B. melitensis (3) A104-13 210739, Mainz AM1,3 1884
B. suis (1) NCTC 10316 1330 A1,3 5167
B. suis (2) A 104–14 Rostock A1,3 10316
B. neotomae A148-7 5 K33 A1,3 1875
Other bacteria
F. tularensis tularensis ATCC 6223 D4 18
F. tularensis holarctica NCTC 10857 D4 22
B. anthracis (spores) Böhm 73202.2000 (PX02) D5 19
S. typhimurium ATCC 14028 D6 19
Y. enterocolitica 310 (IT2, ST9) O9 A7,8,9 1291
Y. pestis CO92 R10 20
O. anthropi ATCC 49188 D11 20
E. coli O157, 15326 A7,12 22
B. mallei NCTC 03709 106 D13 18
B. pseudomallei H05410-0490 D14 20
V. cholera O1, ATCC 14734 A15 24
Luminex LOD was defined as two times the mean fluorescence intensity of the blank (mean blank = 20) and used as the threshold for positive results. Values in
bold indicate positive results. Classification of O-antigens [4, 26–29, 41–50]: A = α1,2-linked 4-amino-4,6-dideoxy-α-D-mannopyranosyl subunits, M = α1,3-linked
and α1,2-linked 4,6-dideoxy-4-formamido-α-D-mannopyranosyl residues, D = different O-antigen structure compared to Brucella, R = ‘rough’ LPS (no O-antigen).
Meikle et al. 19891, Adone et al. 20112, Corbel 20063, Wang et al. 20114, Crich and Vinogradova 20075, Watson et al. 19926, Perry et al. 19867, Caroff et al. 19848,
Bundle et al. 19849, Skurnik et al. 200010, Velasco et al. 199611, Perry and Bundle 199012, Burtnick et al. 200213, Perry et al. 199514, Kenne et al. 198215
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reactivity with Y. enterocolitica serotype O9. The-O-
antigens of Y. enterocolitica O9, E. coli O157, V. cholera
O1 and B. abortus all consist of a linear polymer of α1,2-
linked 4-amino-4,6-dideoxy-α-D-mannopyranosyl resi-
dues (perosamine). However, they differ in the N-acyl-
ation of the perosamine sugar [26]. While B. abortus and
Y. enterocolitica O9 are N-acylated with formic acid, V.
cholera O1 are substituted with (S)-2,4-dihydroxybuta-
noic acid [36]. These derivatisations can have major ef-
fects on antibody binding, which may explain why our
mAbs only showed cross-reactivity with Y. enterocoli-
tica O9. PCR can verify whether a result obtained with
mAb pair 3D12/ 10D1 is true or false positive due to Y.
enterocolitica O9 contamination. To conclusively ana-
lyse environmental samples a combination of molecular
and immunological methods is recommended [37]. Our
mAbs are specific to Brucella carrying ‘smooth’ LPS,
hence a detection of ‘rough’ Brucella species is not pos-
sible. A LPS-independent detection based on surface-
exposed structures might solve this problem.
Depending on the Brucella species tested, the assay
was able to detect 10 to 4000 cells in a sample volume
of 50 μL. Currently available molecular identification as-
says for Brucella spp. offer comparable or even lower de-
tection limits [32, 33, 38].
Recently, a capture ELISA for diagnostic purposes was
developed using LPS-specific monoclonal antibodies to
detect LPS antigens in the blood [39]. Both, our approach
for generating LPS-specific monoclonal antibodies, as well
as the overall purpose of our test development were differ-
ent. We developed a highly sensitive Luminex multiplex
assay for the detection of biological threat agents both in
natural outbreak and bio-threat situations.
The conversion of the ELISA into the Luminex bead-
based assay markedly increased the sensitivity for
detecting Brucella and allowed integration of the Bru-
cella assay into a multiplex assay to simultaneously de-
tect a range of relevant bio-threat species. The
multiplexed immunodetection assay accurately detected
Brucella spp., B. anthracis, F. tularensis and Y. pestis
cells within a single mixed sample. Brucellosis is trans-
mitted to humans through consumption of unpasteur-
ised dairy products or through direct contact with
infected animals. Although detecting Brucella cells in milk
is complicated [40], the Luminex multiplex assay specific-
ally identified all tested bacterial species from spiked milk
samples, demonstrating that the developed assay is a suit-
able tool for detecting Brucella cells in complex samples.
Conclusion
The Luminex assay described here is a suitable tool for
specifically detecting Brucella spp. even in complex sam-
ples such as milk. Four bio-threat agents can be detected
in the multiplex format, quickly and specifically. Overall,
using the Luminex assay together with common molecu-
lar and cultivation methods is crucial to fulfilling inter-
national biodefense regulations for rapidly and reliably
identifying biological threat agents. In the future, the
Luminex assay may also be considered for detecting
Brucella in clinical samples.
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concentration of 2.5 × 106 cells/mL. MAbs 3D12, MTA1, T14 and YPF19, coupled to distinct magnetic beads, were used as capture antibodies and the
biotinylated mAbs 10G1, MTD6, FB11 and YPF19 were used for detection. Reporter dye fluorescence intensities measured for each bead set are shown.
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